10 million Euros to keep moving
21.11.2012 - The Dutch biotech company Kiadis BV has raised €10m in a financing round led by its largest investor.
This round was led by the Company’s largest shareholder Life Sciences Partners and supported by a large investment from DFJ-Esprit, a tech investor based in London. Other financiers included Alta Partners (San Francisco), Quest for Growth (Netherlands) and NOM, the regional development for Northern Netherlands. Kiadis Pharma is specialised on developing treatments for blood cancer and related diseases.
The company's most advanced project is ATIR, which focuses on donor immune cells in which the alloreactive T-cells that would otherwise attack the patient’s body have been selectively eliminated. The cells are infused in the patient about 30 days after the patient has undergone a stem cell transplantation in which all immune cells have been depleted from the graft of the donor.
The financing will enable Kiadis Pharma to perform a confirmatory multi-centre Phase II proof-of-concept study with its lead product and to prepare a pivotal Phase II/III study. Manfred Ruediger, CEO of Kiadis Pharma and Venture Partner at Kiadis shareholder LSP, commented: “We are delighted with the enthusiastic support from existing and new investors, which attests to the exciting clinical data generated for ATIR so far and to the progress the company has achieved over the last year. We are determined to advance ATIR in close cooperation with our clinical investigators in North America and Europe.” Kiadis Pharma merged in 2007 with the Canadian Biotech Celmed Biosciences.